Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.72 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15739372 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL2450650 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL1741931 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL4669761 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15739333 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15739351 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19352015 | 0.98 | FOLH1 (0.97) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL17573317 | 0.95 | FOLH1 (0.90) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL23839908 | 0.93 | FOLH1 (0.87) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12572609 | 0.91 | FOLH1 (0.83) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-26 | — | — | US | claimed |
| US-20260061082-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED DEEP-TUMOR PENETRATION OF POLYMER NANODRUGS AND METHODS OF USE THEREOF | SANTI DANIEL V (US) | 2026-03-05 | — | — | US | claimed |
| EP-4676472-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4594502-A2 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | Ohio State Innovation Foundation (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2024191886-A9 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | PURDUE RESEARCH FOUNDATION (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024191886-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | PURDUE RESEARCH FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-20240165241-A1 | TARGETED DELIVERY OF DRUG MOLECULES WITH DRUG LIGANDS CONJUGATED TO RNA NANOPARTICLE MOTION ELEMENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-23 | — | — | US | claimed |
| WO-2024081511-A2 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-04-18 | — | — | WO | claimed |
| WO-2024050440-A2 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED DEEP-TUMOR PENETRATION OF POLYMER NANODRUGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-07 | — | — | WO | claimed |
| US-20190117799-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-25 | — | — | US | claimed |
| WO-2017173453-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-10-05 | — | — | WO | claimed |
| US-20160151298-A1 | DOCETAXEL POLYMERIC NANOPARTICLES AND METHODS OF TREATING CANCERS USING SAME | BIND THERAPEUTICS, INC. | 2016-06-02 | — | — | US | claimed |
| EP-3013320-A1 | DOCETAXEL POLYMERIC NANOPARTICLES FOR CANCER TREATMENT | BIND Therapeutics, Inc. (US) | 2016-05-04 | — | — | EP | claimed |
| WO-2014210485-A1 | DOCETAXEL POLYMERIC NANOPARTICLES FOR CANCER TREATMENT | BIND THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | claimed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | claimed |
| EP-2097111-A2 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2009-09-09 | — | — | EP | claimed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | claimed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| CN-122094717-A | Targeting ligands for disease-targeting imaging agents and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151298-A1 | DOCETAXEL POLYMERIC NANOPARTICLES AND METHODS OF TREATING CANCERS USING SAME | TP53, TSG101, DSTN | FOLH1 377/4885NAALAD2 3436/4885RIMKLA 4641/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885 |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885 |
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | RNMT, NSUN2, FBL | FOLH1 241/4885NAALAD2 910/4885RIMKLA 3739/4885 |
| US-20190117799-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | HSPA9, LRBA, AHSA1 | FOLH1 4319/4885NAALAD2 2713/4885RIMKLA 3618/4885 |
| US-20260061082-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED DEEP-TUMOR PENETRATION OF POLYMER NANODRUGS AND METHODS OF USE THEREOF | KLK3, FOLH1, SLC14A1 | FOLH1 2/4885NAALAD2 726/4885RIMKLA 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.